These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16985047)

  • 21. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
    Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
    Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
    Heim M; Scharifi M; Zisowsky J; Jaehde U; Voliotis D; Seeber S; Strumberg D
    Anticancer Drugs; 2005 Feb; 16(2):129-36. PubMed ID: 15655409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins.
    Horibe S; Matsuda A; Tanahashi T; Inoue J; Kawauchi S; Mizuno S; Ueno M; Takahashi K; Maeda Y; Maegouchi T; Murakami Y; Yumoto R; Nagai J; Takano M
    Life Sci; 2015 Mar; 124():31-40. PubMed ID: 25625243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
    Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
    Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
    Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.
    Hellberg V; Wallin I; Eriksson S; Hernlund E; Jerremalm E; Berndtsson M; Eksborg S; Arnér ES; Shoshan M; Ehrsson H; Laurell G
    J Natl Cancer Inst; 2009 Jan; 101(1):37-47. PubMed ID: 19116379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines.
    Kashiwagi E; Izumi H; Yasuniwa Y; Baba R; Doi Y; Kidani A; Arao T; Nishio K; Naito S; Kohno K
    Cancer Sci; 2011 Feb; 102(2):382-6. PubMed ID: 21087353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.
    Chiu SJ; Lee YJ; Hsu TS; Chen WS
    Chem Biol Interact; 2009 Dec; 182(2-3):173-82. PubMed ID: 19735649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. γ-Aminobutyric acid inhibits the proliferation and increases oxaliplatin sensitivity in human colon cancer cells.
    Song L; Du A; Xiong Y; Jiang J; Zhang Y; Tian Z; Yan H
    Tumour Biol; 2016 Nov; 37(11):14885-14894. PubMed ID: 27644246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.
    Boyer J; Allen WL; McLean EG; Wilson PM; McCulla A; Moore S; Longley DB; Caldas C; Johnston PG
    Cancer Res; 2006 Mar; 66(5):2765-77. PubMed ID: 16510598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines.
    Atallah D; Marsaud V; Radanyi C; Kornprobst M; Rouzier R; Elias D; Renoir JM
    Int J Hyperthermia; 2004 Jun; 20(4):405-19. PubMed ID: 15204521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
    Toscano F; Parmentier B; Fajoui ZE; Estornes Y; Chayvialle JA; Saurin JC; Abello J
    Biochem Pharmacol; 2007 Aug; 74(3):392-406. PubMed ID: 17559811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
    Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
    Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway.
    Jelínková I; Šafaříková B; Vondálová Blanářová O; Skender B; Hofmanová J; Sova P; Moyer MP; Kozubík A; Kolář Z; Ehrmann J; Hyršlová Vaculová A
    Biochem Pharmacol; 2014 Dec; 92(3):415-24. PubMed ID: 25285768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells.
    Varma R; Hector S; Greco WR; Clark K; Hawthorn L; Porter C; Pendyala L
    Cancer Chemother Pharmacol; 2007 May; 59(6):711-23. PubMed ID: 17021820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard.
    Fan S; Chang JK; Smith ML; Duba D; Fornace AJ; O'Connor PM
    Oncogene; 1997 May; 14(18):2127-36. PubMed ID: 9174048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Down-regulation of p110β expression increases chemosensitivity of colon cancer cell lines to oxaliplatin.
    Liu W; Wang G; Cao X; Luo X; Li Z; Deng Y; Li X; Wang S; Liu M; Hu J; Wang J
    J Huazhong Univ Sci Technolog Med Sci; 2012 Apr; 32(2):280-286. PubMed ID: 22528234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10.
    Varma RR; Hector SM; Clark K; Greco WR; Hawthorn L; Pendyala L
    Oncol Rep; 2005 Oct; 14(4):925-32. PubMed ID: 16142353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.